Precigen (PGEN) Capital Leases (2012 - 2013)
Precigen (PGEN) posted quarterly Capital Leases of $10000.0 for Q4 2013, down 76.19% year-over-year from $42000.0 in Q4 2012, and down 37.5% quarter-over-quarter from $16000.0 in Q3 2013.
Precigen (PGEN) Capital Leases (2012 - 2013) Analysis & Trends
Precigen (PGEN) has reported Capital Leases for 2 consecutive years, with $10000.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Capital Leases fell 76.19% year-over-year to $10000.0; the TTM figure through Dec 2013 stood at $10000.0 (down 76.19% YoY), while the FY2013 annual figure was $10000.0, down 76.19% from the prior year.
- Capital Leases fell to $10000.0 in Q4 2013 per PGEN's latest filing, from $16000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $42000.0 in Q4 2012 and bottomed at $10000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 10,000.00 |
| Sep 30, 2013 | 16,000.00 |
| Jun 30, 2013 | 25,000.00 |
| Dec 31, 2012 | 42,000.00 |